A Phase 3 interventional study of GWP42003-P in Tuberous Sclerosis Complex and Seizures, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 1 Year to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-14.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Tuberous Sclerosis with a site in United States — 8 open to participants now, 15 under way, 1 of them phase 3. Tuberous Sclerosis · United States.
Among the 63 studies in Tuberous Sclerosis with a site in United States, this one is the 4th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2016, is one of 10 in phase 3, and was the 30th registered.
115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.
Browse Tuberous Sclerosis studies →8 of the 63 studies in Tuberous Sclerosis with a site in United States are open now. Recruiting first, the newest first:
David M. Ritter · Sites in United States
Women only
St. Jude Children's Research Hospital · Sites in United States
National Tuberous Sclerosis Association · Sites in United States, Canada
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–90
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 2–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 1 Year to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 11 · Phase 4 3
First in 1995; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 52 across 73 interventional studies indexed under Tuberous Sclerosis.
Median enrollment 52 across the 47 interventional studies, 300 across the 15 observational. Of the 44 that completed or were terminated, 25 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 63 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 6 studies filed under Tuberous Sclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Tuberous Sclerosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT06879665Vrije Universiteit BrusselTANDem-2: Closing the Gap to Interventions for TAND | 2026-12-31 |
| NCT05104983Darcy KruegerStopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | 2027-06-30 |
| NCT05044819Jazz PharmaceuticalsAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 63 studies in Tuberous Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.
Key Inclusion Criteria:
100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
Drug: GWP42003-P
Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Also known as: Cannabidiol, CBD
Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)
An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.
Time frame: OLE Day 1 up to 4 years
Number of Participants With Any TEAE, by Severity
An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. Grade 1 (Mild) is defined as asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate) is defined as minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL). Grade 3 (Severe) is defined as medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
Time frame: OLE Day 1 up to 4 years
Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period
TSC-associated seizures include: focal motor seizures without impairment of consciousness or awareness; focal seizures with impairment of consciousness or awareness; focal seizures evolving to bilateral generalized convulsive seizures and tonic-clonic, tonic, clonic or atonic seizures. A negative percent change from baseline indicates improvement.
Time frame: OLE Day 1 up to 4 years
Number of Participants Considered Treatment Responders During the OLE Treatment Period
Treatment responders were defined as those participants with a ≥50% reduction from baseline in TSC-associated seizure frequency, during the treatment period, for participants who had not withdrawn from the trial during the treatment period. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. Participants who withdrew from the trial during the treatment period were considered non-responders.
Time frame: OLE Day 1 up to 4 years
Caregiver Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC) Score During the OLE Treatment Period
The CGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)." The average CGIC and SGIC scores are being reported, with higher values indicating worse condition.
Time frame: OLE Day 1 and up to 4 years
Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period
Total seizures included all seizure types, eg. combination of TSC-associated and other seizures. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. A negative percent change from baseline indicates improvement in total seizure frequency.
Time frame: OLE Day 1 up to 4 years
A total of 199 participants with tuberous sclerosis complex (TSC) who met all inclusion criteria and no exclusion criteria and completed the double-blind study GWEP1521 (NCT02544763) were enrolled into this Open-label Extension (OLE) study to receive GWP42003-P.
| Milestone | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Started | 124 | 75 |
| Completed | 22 | 12 |
| Not completed | 102 | 63 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Other reasons | 69 | 39 |
| Withdrew: Met withdrawal criteria | 2 | 2 |
| Withdrew: Transition to commercial product | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 8 | 7 |
| Withdrew: Adverse event | 8 | 10 |
| Withdrew: Withdrawal by subject | 10 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.
| Participants | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Any TEAE | 117 | 75 |
| Any treatment-related TEAE | 80 | 60 |
| Any TEAE leading to permanent discontinuation of IMP | 11 | 7 |
| Any treatment-related TEAE leading to permanent discontinuation of IMP | 9 | 7 |
| Any serious TEAE | 38 | 18 |
| Any treatment-related serious TEAE | 7 | 8 |
| Any fatal TEAEs | 1 | 0 |
An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. Grade 1 (Mild) is defined as asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate) is defined as minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL). Grade 3 (Severe) is defined as medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
| Participants | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Mild TEAE | 35 | 16 |
| Moderate TEAE | 63 | 48 |
| Severe TEAE | 19 | 11 |
TSC-associated seizures include: focal motor seizures without impairment of consciousness or awareness; focal seizures with impairment of consciousness or awareness; focal seizures evolving to bilateral generalized convulsive seizures and tonic-clonic, tonic, clonic or atonic seizures. A negative percent change from baseline indicates improvement.
| percent change | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period | -55.66 (-86.47 to -12.33) | -46.76 (-78.17 to -15.69) |
Treatment responders were defined as those participants with a ≥50% reduction from baseline in TSC-associated seizure frequency, during the treatment period, for participants who had not withdrawn from the trial during the treatment period. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. Participants who withdrew from the trial during the treatment period were considered non-responders.
| Participants | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| ≥ 50% reduction: Yes | 70 | 36 |
| ≥ 50% reduction: No | 54 | 39 |
The CGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)." The average CGIC and SGIC scores are being reported, with higher values indicating worse condition.
| score on a scale | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Caregiver | 3.2 ± 1.58 | 3.4 ± 1.12 |
| Subjects | 4.0 ± 0.0 | 2.7 ± 1.53 |
| Combined Caregiver and Subjects | 3.2 ± 1.56 | 3.3 ± 1.16 |
Total seizures included all seizure types, eg. combination of TSC-associated and other seizures. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. A negative percent change from baseline indicates improvement in total seizure frequency.
| percent change | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period | -55.18 (-84.21 to -11.95) | -46.76 (-76.22 to -19.77) |
Collected over Treatment-emergent adverse events (TEAEs) were collected from OLE Day 1 up to 4 years.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Double-blind Phase) | 1/124 (0.8%) | 38/124 (30.6%) | 117/124 (94.4%) |
| GWP42003-P (Double-blind Phase) | 0/75 (0%) | 18/75 (24%) | 75/75 (100%) |
| Event | Placebo (Double-blind Phase) | GWP42003-P (Double-blind Phase) |
|---|---|---|
| SeizureNervous system disorders | 12/124 | 4/75 |
| Status epilepticusNervous system disorders | 9/124 | 1/75 |
| InfluenzaInfections and infestations | 5/124 | 0/75 |
| PneumoniaInfections and infestations | 4/124 | 1/75 |
| DehydrationMetabolism and nutrition disorders | 4/124 | 2/75 |
| Transaminases increasedInvestigations | 0/124 | 2/75 |
| Adenovirus infectionInfections and infestations | 2/124 | 0/75 |
| Mental status changesPsychiatric disorders | 2/124 | 0/75 |
| NeutropeniaBlood and lymphatic system disorders | 0/124 | 1/75 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/124 | 1/75 |
| Event | Placebo (Double-blind Phase) | GWP42003-P (Double-blind Phase) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 50/124 | 43/75 |
| SeizureNervous system disorders | 40/124 | 19/75 |
| Decreased appetiteMetabolism and nutrition disorders | 23/124 | 24/75 |
| SomnolenceNervous system disorders | 15/124 | 24/75 |
| PyrexiaGeneral disorders | 33/124 | 15/75 |
| VomitingGastrointestinal disorders | 27/124 | 13/75 |
| NasopharyngitisInfections and infestations | 19/124 | 16/75 |
| Upper respiratory tract infectionInfections and infestations | 22/124 | 10/75 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/124 | 13/75 |
| FatigueGeneral disorders | 7/124 | 10/75 |
| Age, Continuous(years) | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) | Total |
|---|---|---|---|
| Mean | 12.69 ± 9.64 | 13.92 ± 10.63 | 13.15 ± 10.02 |
| Sex: Female, Male(Participants) | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) | Total |
|---|---|---|---|
| Female | 51 | 30 | 81 |
| Male | 73 | 45 | 118 |
| Race/Ethnicity, Customized(Participants) | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) | Total |
|---|---|---|---|
| White/Caucasian | 111 | 66 | 177 |
| Black/African American | 4 | 0 | 4 |
| American Indian/Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 3 | 4 |
| Other | 7 | 6 | 13 |
| Baseline Tuberous Sclerosis Complex (TSC)-Associated Seizures(Seizures) | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) | Total |
|---|---|---|---|
| Median | 58.08 (7.7 to 432.0) | 55.10 (8.0 to 558.0) | 56.90 (7.7 to 558.0) |
| Baseline Total Seizures(Seizures) | GWP42003-P (Double-blind Phase) | Placebo (Double-blind Phase) | Total |
|---|---|---|---|
| Median | 59.95 (7.7 to 595.0) | 56.97 (8.0 to 1660.1) | 58.90 (7.7 to 1660.1) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2016 to primary completion in Jun 2021, 57 months.
Results were first posted in Jul 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol